Clinical significance of positive Pneumocystis jirovecii polymerase chain reaction in non-human immunodeficiency virus immunocompromised patients in a real practice
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Pneumocystis jirovecii polymerase chain reaction (PCR) can be helpful in diagnosing Pneumocystis pneumonia (PCP); however it has limitations. We evaluated the prevalence of positive P. jirovecii PCR from non-human immunodeficiency virus (HIV) immunocompromised patients and tried to determine the risk of PCP development. Methods: Between May 2009 and September 2012, P. jirovecii PCR was performed in bronchoscopic specimens from 1,231 adult non-HIV immunocompromised patients suspected of respiratory infection. Only 169 patients (13.7%) who were tested positive for P. jirovecii PCR were enrolled. Retrospective chart review was performed. PCP was defined in patients with positive P. jirovecii PCR who were treated for PCP based on the clinical decision. Results: From 169 P. jirovecii PCR-positive patients, 90 patients were in the PCP group (53.3%) and 79 patients were in the non-PCP group (46.7%). In the PCP group, 38% of patients expired or aggravated after therapy, whereas the majority of patients (84%) in the non-PCP group recovered without treatment for PCP. Independent risk factors for PCP by binary logistic regression analysis were underlying conditions- hematological malignancies, solid tumors or solid organ transplantation, dyspnea, age < 60 years, and albumin < 2.9 g/dL. Conclusions: This study suggests that not all P. jirovecii PCR-positive patients need to be treated for PCP. Among P. jirovecii PCR-positive patients, those who are less than 60 years old, with hematological malignancies, solid tumors or solid organ transplantation, low albumin, and with symptoms of dyspnea, the possibility of PCP might be higher. Treatment should also be selected to these patients.
Abstract
Background/Aims: Pneumocystis jirovecii polymerase chain reaction (PCR) can be helpful in diagnosing Pneumocystis pneumonia (PCP); however it has limitations. We evaluated the prevalence of positive P. jirovecii PCR from non-human immunodeficiency virus (HIV) immunocompromised patients and tried to determine the risk of PCP development. Methods: Between May 2009 and September 2012, P. jirovecii PCR was performed in bronchoscopic specimens from 1,231 adult non-HIV immunocompromised patients suspected of respiratory infection. Only 169 patients (13.7%) who were tested positive for P. jirovecii PCR were enrolled. Retrospective chart review was performed. PCP was defined in patients with positive P. jirovecii PCR who were treated for PCP based on the clinical decision. Results: From 169 P. jirovecii PCR-positive patients, 90 patients were in the PCP group (53.3%) and 79 patients were in the non-PCP group (46.7%). In the PCP group, 38% of patients expired or aggravated after therapy, whereas the majority of patients (84%) in the non-PCP group recovered without treatment for PCP. Independent risk factors for PCP by binary logistic regression analysis were underlying conditions- hematological malignancies, solid tumors or solid organ transplantation, dyspnea, age < 60 years, and albumin < 2.9 g/dL. Conclusions: This study suggests that not all P. jirovecii PCR-positive patients need to be treated for PCP. Among P. jirovecii PCR-positive patients, those who are less than 60 years old, with hematological malignancies, solid tumors or solid organ transplantation, low albumin, and with symptoms of dyspnea, the possibility of PCP might be higher. Treatment should also be selected to these patients.
참고문헌 (30)
- Thomas CF Jr, "Pneumocystis pneumonia", N Engl J Med, 350, pp.2487~2498 (2004)
- Overgaard UM, "Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004", Scand J Infect Dis, 39, pp.589~595 (2007)
- Roblot F, "Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients", Eur J Clin Microbiol Infect Dis, 21, pp.523~531 (2002)
- Reid AB, "Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools", Curr Opin Infect Dis, 24, pp.534~544 (2011)
- Morris A, "Epidemiology and clinical significance of pneumocystis colonization", J Infect Dis, 197, pp.10~17 (2008)
- Leibovitz E, "Comparison of PCR and standard cytological staining for detection of Pneumocystis carinii from respiratory specimens from patients with or at high risk for infection by human immunodeficiency virus", J Clin Microbiol, 33, pp.3004~3007 (1995)
- Lipschik GY, "Improved diagnosis of Pneumocystis carinii infection by polymerase chain reaction on induced sputum and blood", Lancet, 340, pp.203~206 (1992)
- Mekinian A, "Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome", Rheumatology (Oxford), 50, pp.569~577 (2011)
- Wakefield AE, "Detection of Pneumocystis carinii with DNA amplification", Lancet, 336, pp.451~453 (1990)
- Kovacs JA, "Evolving health effects of Pneumocystis:one hundred years of progress in diagnosis and treatment", JAMA, 301, pp.2578~2585 (2009)
- The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia., "Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome", N Engl J Med, 323, pp.1500~1504 (1990)
- ARDS Definition Task Force, "Acute respiratory distress syndrome: the Berlin Definition", JAMA, 307, pp.2526~2533 (2012)
- Levy MM, "2001 SCCM", ESICM, ATS, pp.SIS International Sepsis Definitions Conference, Crit Care Med[DOI]
- Marshall JC, "Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome", Crit Care Med, 23, pp.1638~1652 (1995)
- Fishman GI, "Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop", Circulation, 122, pp.2335~2348 (2010)
- Miller RF, "Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia", J Clin Microbiol, 39, pp.3877~3882 (2001)
- Tsolaki AG, "Pre-AIDS era isolates of Pneumocystis carinii f. sp. hominis: high genotype similarity with contemporary isolates", J Clin Microbiol, 36, pp.90~93 (1998)
- Tasaka S, "Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies", J Infect Chemother, 18, pp.793~806 (2012)
- Nevez G, "High frequency of Pneumocystis carinii sp.f. hominis colonization in HIV-negative patients", J Eukaryot Microbiol, 44, pp.36S~ (1997)
- Chabe M, "Immunocompetent hosts as a reservoir of pneumocystis organisms: histological and rt-PCR data demonstrate active replication", Eur J Clin Microbiol Infect Dis, 23, pp.89~97 (2004)
- Morris A, "Colonization by Pneumocystis jirovecii and its role in disease", Clin Microbiol Rev, 25, pp.297~317 (2012)
- Torres HA, "Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients", Eur J Clin Microbiol Infect Dis, 25, pp.382~388 (2006)
- Fritzsche C, "High prevalence of Pneumocystis jirovecii colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy", Scand J Rheumatol, 41, pp.208~213 (2012)
- Mori S, "Asymptomatic carriage of Pneumocystis jiroveci in elderly patients with rheumatoid arthritis in Japan: a possible association between colonization and development of Pneumocystis jiroveci pneumonia during low-dose MTX therapy", Mod Rheumatol, 18, pp.240~246 (2008)
- Kovacs JA, "Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies", Ann Intern Med, 100, pp.663~671 (1984)
- White DA, "The utility of open lung biopsy in patients with hematologic malignancies", Am J Respir Crit Care Med, 161(3 Pt 1), pp.723~729 (2000)
- Fujisawa T, "Real-time PCR is more specific than conventional PCR for induced sputum diagnosis of Pneumocystis pneumonia in immunocompromised patients without HIV infection", Respirology, 14, pp.203~209 (2009)
- Muhlethaler K, "Quantitative PCR to diagnose Pneumocystis pneumonia in immunocompromised non-HIV patients", Eur Respir J, 39, pp.971~978 (2012)
- Matsumura Y, "Quantitative real-time PCR and the (1→3)-β-D-glucan assay for differentiation between Pneumocystis jirovecii pneumonia and colonization", Clin Microbiol Infect, 18, pp.591~597 (2012)
- Tasaka S, "Serum (1 → 3)β-D-glucan assay for discrimination between Pneumocystis jirovecii pneumonia and colonization", J Infect Chemother, 20, pp.678~681 (2014)